Custom Search

News

Saturday 01 September 2001

Intravenous bolus topotecan in patients with myelodysplastic syndrome.

By: Seiter K, Liu D, Feldman EJ, Siddiqui AD, Hoang A, Baskind P, Kancherla R, Ahmed T.

Leuk Lymphoma 2001 Sep-Oct;42(5):963-8

We treated 16 patients with myelodysplastic syndromes with 24 courses of bolus topotecan. Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m2/d, 2.0 mg/m2/d or 2.5 mg/m2/d). There was one complete response and one partial response (overall response rate 12%). Toxicity included myelosuppression, diarrhea, ileus and mucositis. There were 3 treatment-related deaths. The results of this schedule of topotecan appeared to be inferior to that reported with infusional topotecan in patients with MDS.

Use of this site is subject to the following terms of use